Condition: Hip Arthritis · Hip Disease · Hip Fractures · Sponsor: Zimmer Biomet
The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up\*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.
This description comes directly from the study's public registry record.
Megan McKinnie · +1 (919) 381-7091 · megan.mckinnie@zimmerbiomet.com
Lynsey Boyle · +1 (412) 552-7111 · Lynsey.Boyle@zimmerbiomet.com
Always discuss trial participation with your own doctor first.
| Orthopaedic Institute of Henderson | Henderson, Nevada, United States | Withdrawn |
| Texas Health Physicians Group | Plano, Texas, United States | Recruiting |
| Proliance Orthopaedics and Sports Medicine | Bellevue, Washington, United States | Withdrawn |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04028687